APA (7th ed.) Citation

PH, L., CH, L., PC, C., YC, Y., PW, C., CF, F., . . . CY, C. (2026). Mitigating unfavourable treatment outcomes and acquired rifampicin resistance in isoniazid-resistant tuberculosis: The role of fluoroquinolone. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 59(2), 244. https://doi.org/10.1016/j.jmii.2025.08.012

Chicago Style (17th ed.) Citation

PH, Lee, Liu CH, Chan PC, Yang YC, Chu PW, Feng CF, Lo HY, Lee CC, and Chiang CY. "Mitigating Unfavourable Treatment Outcomes and Acquired Rifampicin Resistance in Isoniazid-resistant Tuberculosis: The Role of Fluoroquinolone." Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi 59, no. 2 (2026): 244. https://doi.org/10.1016/j.jmii.2025.08.012.

MLA (9th ed.) Citation

PH, Lee, et al. "Mitigating Unfavourable Treatment Outcomes and Acquired Rifampicin Resistance in Isoniazid-resistant Tuberculosis: The Role of Fluoroquinolone." Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi, vol. 59, no. 2, 2026, p. 244, https://doi.org/10.1016/j.jmii.2025.08.012.